Reduction of relapse risk through incorporation of novel biologic agents following reduced intensity haploidentical donor transplant for acute myeloid leukemia

Ended Cooperative Agreement Awarded Last action

Award ID
UG1HL109526
Recipient
Awarding agency
Obligated
$1,074,217

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date
Funding
  • $920,117.14 Federal
  • $154,100.00 Non-federal
Place of performance
Atlanta, GA 30342, USA

Award details come from USAspending.gov.

Transactions

Action Federal Non-federal Date
Amendment -$152,051 $0
Amendment -$153,075 $0
Amendment -$31,087 $0
Amendment $152,051 $0
Amendment -$91,957 $0
Amendment -$91,957 $0
Amendment -$91,957 $0
Amendment $153,075 $0
Amendment $153,075 $0
Amendment $154,100 $0
Amendment $154,100 $0
Amendment $154,100 $154,100
Amendment $155,199 $0
Amendment $156,263 $0
Amendment $149,563 $0
Amendment $0 $0
Original award $150,674 $0
Show all 17

Quick answers

Who received award UG1HL109526?

UG1HL109526 was awarded to Northside Hospital, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on August 22, 2011.

How much is award UG1HL109526 worth?

$1,074,217 has been obligated on UG1HL109526: $920,117 in federal funding and $154,100 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award